Deutsche Bank upgraded shares of Roche Holdings AG Basel (OTCMKTS:RHHBY) from a hold rating to a buy rating in a report issued on Thursday morning, Briefing.com Automated Import reports.

OTCMKTS:RHHBY opened at $35.60 on Thursday. Roche Holdings AG Basel has a 12 month low of $26.96 and a 12 month high of $35.90. The company has a market capitalization of $243.27 billion, a PE ratio of 15.34, a PEG ratio of 2.57 and a beta of 0.46.

A number of hedge funds have recently made changes to their positions in the stock. Trust Co. of Vermont increased its position in Roche Holdings AG Basel by 1.6% during the first quarter. Trust Co. of Vermont now owns 32,062 shares of the company’s stock worth $1,104,000 after acquiring an additional 505 shares during the period. Kornitzer Capital Management Inc. KS increased its position in Roche Holdings AG Basel by 0.3% during the first quarter. Kornitzer Capital Management Inc. KS now owns 317,960 shares of the company’s stock worth $10,949,000 after acquiring an additional 935 shares during the period. Dearborn Partners LLC increased its position in Roche Holdings AG Basel by 11.9% during the first quarter. Dearborn Partners LLC now owns 9,339 shares of the company’s stock worth $321,000 after acquiring an additional 992 shares during the period. Osher Van de Voorde Investment Management increased its position in Roche Holdings AG Basel by 0.5% during the fourth quarter. Osher Van de Voorde Investment Management now owns 259,128 shares of the company’s stock worth $8,054,000 after acquiring an additional 1,276 shares during the period. Finally, Advisor Partners LLC increased its position in Roche Holdings AG Basel by 6.4% during the first quarter. Advisor Partners LLC now owns 34,553 shares of the company’s stock worth $1,188,000 after acquiring an additional 2,070 shares during the period. 0.30% of the stock is currently owned by institutional investors and hedge funds.

Roche Holdings AG Basel Company Profile

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

Read More: Capital gains and your 401(k) or IRA

Analyst Recommendations for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.